AOH1996 for the Treatment of Refractory Solid Tumors

This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1996 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Trial Details

NCT ID
NCT05227326
Phase
PHASE1
Sponsor
City of Hope Medical Center
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • PCNA Inhibitor AOH1996
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Duarte, California, United States|34.13945,-117.97729

Key Eligibility Criteria

  • Informed Consent and Willingness to Participate
  • 1\. Documented informed consent by the participant
  • 2\. Willingness to permit study team to obtain and use archival tissue, if already existing
  • Age Criteria, Performance Status and Life Expectancy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →